Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

WHO: Nations mulling Gilead's COVID drug should consider trial flop, too

10/23/2020 | 12:28pm EST

GENEVA/ZURICH, Oct 23 (Reuters) - Health officials reviewing Gilead Science Inc's remdesivir against COVID-19 should consider all evidence, including a trial in which the medicine failed, before giving it the green light, the top WHO scientist said on Friday.

U.S. regulators appeared not to have done so when approving the drug this week, Soumya Swaminathan told a news conference.

The U.S. Food and Drug Administration on Thursday approved Gilead's antiviral drug for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

The FDA decision came a week after the release of the results of the World Health Organization's Solidarity trial, which concluded remdesivir has little or no impact on a patient's chances of surviving COVID-19.

The FDA said its approval was based on three trials, including a 1,062-patient study by the National Institute of Allergy and Infectious Disease, which found that remdesivir reduced hospital stays to 10 days from 15 days, and helped reduce the risk of death in some patients who were receiving oxygen. The drug did not improve overall survival.

"The Solidarity results do not refute these findings of benefit to patients," the FDA said in a statement posted on its website.

Remdesivir is also approved for treatment of patients with severe COVID-19 in Japan, Taiwan, India, Singapore, the United Arab Emirates and the European Union. Gilead is allowing generic companies to manufacture the drug for supply to 127 low-income countries.

"We believe our results are very robust," the WHO's Swaminathan said, when asked about the FDA move. "We hope that people who are doing treatment guidelines in other countries, as well as regulators around the world, will take note of our study results, in addition to the other evidence."

For the remdesivir arm of the WHO's Solidarity trial, 2,743 patients were given the treatment, compared to 2,708 in the control group.

Gilead, which has raised the possibility of bias in the "unblinded" WHO study because patients and their doctors were aware of which treatments were being used, got initial data from the trial in late September, the WHO has said.

"We have apprised FDA of the topline WHO Solidarity trial results and the draft manuscript" submitted to a publication, the company said. "However, at this time Gilead has not received the requested datasets from WHO for the Solidarity trial results."

The WHO also said on Friday that its formal guidelines on use of remdesivir for COVID-19 should be ready for release in three to four weeks, after a separate group within the United Nations health agency reviews data from the study.

An independent WHO panel will convene next week to look at all evidence of the effectiveness of Gilead's drug, Janet Diaz, the WHO's top official for clinical care responses, said.

"We would anticipate that the guidelines will be available within three to four weeks," Diaz said. "What we're doing now in the pandemic is to try to continue with that approach in a transparent and trustworthy way, but do it faster." (Reporting by John Miller, Stephanie Nebehay and Michael Shields; Additional reporting by Deena Beasley in Los Angeles; Writing by Peter Graff and John Miller; Editing by Kevin Liffey, Andrew Cawthorne and Richard Chang)

© Reuters 2020
All news about GILEAD SCIENCES, INC.
02:49pEU seeks to bypass patents to boost drugs access in crises
11/24GILEAD SCIENCES : to Present at the 3rd Annual Evercore ISI HealthCONx Conferenc..
11/23GILEAD SCIENCES : to Present at the 3rd Annual Evercore ISI HealthCONx Conferenc..
11/23Canada could approve COVID-19 vaccines early next year -regulator
11/23GILEAD SCIENCES : U.S. infectious disease group backs Gilead's remdesivir for CO..
11/21FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug -- Update
11/20WALL STREET STOCK EXCHANGE : Stocks decline as COVID-19 cases surge
11/20NEWS HIGHLIGHTS : Top Company News of the Day
11/20Health Care Down, But Not By Much, Amid Vaccine Optimism -- Health Care Round..
11/20Post Holdings, Gilead Sciences fall; Pfizer, Hibbett rise
More news
Financials (USD)
Sales 2020 23 650 M - -
Net income 2020 34,3 M - -
Net Debt 2020 20 525 M - -
P/E ratio 2020 -4 420x
Yield 2020 4,52%
Capitalization 75 525 M 75 525 M -
EV / Sales 2020 4,06x
EV / Sales 2021 3,87x
Nbr of Employees 11 800
Free-Float 99,6%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 73,52 $
Last Close Price 60,25 $
Spread / Highest target 74,3%
Spread / Average Target 22,0%
Spread / Lowest Target -3,73%
EPS Revisions
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.55.32%38 761
BIONTECH SE200.68%24 529
BEIGENE, LTD.54.55%23 352